Prescription drug · BLA
Rebyota (Donor human stool) NDC 55566-9800
Donor human stool 50000000000 [CFU]/150mL · Suspension · Rectal · Ferring Pharmaceuticals Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 55566-9800-2 | 55566980002 | 1 CARTON in 1 CARTON (55566-9800-2) / 1 BAG in 1 CARTON (55566-9800-1) / 150 mL in 1 BAG (55566-9800-0)Marketed from Jan 9, 2023 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Rebyota
- Generic name (nonproprietary)
- donor human stool
- Active ingredients
- Donor human stool — 50000000000 [CFU]/150mL
- Dosage form
- Suspension
- Route
- Rectal
- Labeler
- Ferring Pharmaceuticals Inc.NDC labeler code 55566
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 125739
- Marketing start
- Listing expires
- Identifiers
- Product ID 55566-9800_2484fbb1-68f0-4bae-890e-8a208e5d3c7aSPL ID 2484fbb1-68f0-4bae-890e-8a208e5d3c7aSPL set ID 7af8a7f6-a441-4dc6-a151-138a89166fbbRxCUI 2626732, 2626737UNII 3TVP4E28JR
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N455566980002followed by a unit qualifier and the quantityPackage 55566-9800-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. ( 1 ) Limitation of Use: REBYOTA is not indicated for treatment of CDI. Limitation of Use: REBYOTA is not indicated for treatment of CDI.
Excerpt only. Read the full label for complete information.
About NDC 55566-9800
- What is NDC 55566-9800?
- 55566-9800 is the product NDC for Rebyota (donor human stool), Donor human stool 50000000000 [CFU]/150mL suspension, listed with the FDA by Ferring Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Rebyota (Donor Human Stool).
- What is the active ingredient?
- Donor human stool.
- Who is the labeler?
- Ferring Pharmaceuticals Inc., NDC labeler code 55566. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Rebyota?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.